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Evaluation of the Interaction between Phosphohistidine
Analogues and Phosphotyrosine Binding Domains
Tom E. McAllister, Katherine A. Horner, and Michael E. Webb*[a]
We have investigated the interaction of peptides containing
phosphohistidine analogues and their homologues with the
prototypical phosphotyrosine binding SH2 domain from the
eukaryotic cell signalling protein Grb2 by using a combination
of isothermal titration calorimetry and a fluorescence anisotro-
py competition assay. These investigations demonstrated that
the triazole class of phosphohistidine analogues are capable of
binding too, suggesting that phosphohistidine could potential-
ly be detected by this class of proteins in vivo.
Phosphorylation of proteins is well established as a dominant
mechanism of signal transduction in eukaryotic cells.[1] Phos-
phorylation occurs in response to extracellular and intracellular
signals, and the modified protein can then be sensed by se-
quence-specific modular binding domains.[2] These include SH2
and PTB domains, which bind phosphotyrosine,[3] and 14-3-3
and WW domains, which bind phosphothreonine and phos-
phoserine.[4] In contrast, it is still unknown how, or indeed
whether, other phosphorylated amino acids such as phospho-
histidine are sensed. The lability of this latter modification
means that it has only been directly observed in a limited
subset of eukaryotic proteins, including the cystic fibrosis
transmembrane receptor (CFTR),[5] histone H4[6] and the potas-
sium-activated calcium channel KCa3.1.[7] In the first and last
cases, histidine phosphorylation directly activates the channel;
however, in the case of histone H4 and many others, the func-
tion has not been determined. Although proteomic methods[8]
are increasingly able to identify this modification in proteins,
no general function for it has been identified.
We recently reported the synthesis of a triazolyl analogue,
3a, of t-phosphohistidine (1, Scheme 1), which is fully compat-
ible with the Fmoc-protection strategy for solid-phase synthe-
sis.[9] Independently, Kee et al. have demonstrated that, follow-
ing Boc-peptide synthesis, it was possible to use analogue 2 as
a hapten to identify antibodies capable of identifying phos-
phohistidine in a site-specific fashion.[10] More recently a trun-
cated form of 2 has been used to generate a polyclonal anti-
body that is able to identify 1 in a variety of proteins.[11]
The study of phosphoprotein interactions in vitro requires
a source of phosphorylated protein. There are well known
techniques for isolating phosphate ester-containing proteins,
but maintaining phosphorylated histidine residues during pro-
tein isolation is notoriously difficult,[12] even though histidine
can be chemically phosphorylated in vitro.[13] An alternative ap-
proach is the incorporation of phosphoamino acids (or precur-
sors) into recombinant proteins. This approach was used by
Serwa et al. to generate an analogue of phosphotyrosine 4 by
Staudinger phosphite reaction on a genetically incorporated p-
azidophenylalanine to form phosphoramidate 5 (Scheme 2).[14]
A further phosphotyrosine analogue, p-carboxymethylphenyl-
alanine (6),[15] has also been incorporated by an amber-sup-
pression approach; direct genetic incorporation of phosphoser-
ine has also been achieved.[16]
We hypothesised that we could generate a protein contain-
ing our phosphohistidine analogue by first producing a protein
with an azidoalanine residue and subsequent reaction with
a suitably protected alkynyl phosphonate 8. Unfortunately l-
azidoalanine cannot be incorporated by amber suppression
and is only poorly incorporated as a methionine surrogate.[17]
Scheme 1. Structures of t-phosphohistidine (1) and the corresponding tri-
azole-phosphonate mimic, 2, which can be incorporated into peptides by
using precursors 3a and 3b.
Scheme 2. Structures of phosphotyrosine 4 and analogues 5 and 6, which
have previously been incorporated into recombinant proteins.
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However, the homologous compound, l-azidohomoalanine (7),
is well accepted as a methionine surrogate[18] and reaction of
this residue with alkynyl phosphonate 8 would ultimately pro-
duce homotriazole 10 (Scheme 3). Though this triazole could
perhaps no longer mimic phosphohistidine, it occurred to us
that 10 could present the phosphoryl group in a similar orien-
tation to phosphotyrosine (due to the extra flexibility be-
stowed by the g-methylene group) and thus constitute a novel
analogue of phosphotyrosine 4. Though not our primary goal,
investigation of this seemed prudent as, if a suitable mimic, 10
would be a more accessible phosphotyrosine analogue than
the current alternatives.
We envisaged producing suitable peptides by Fmoc-SPPS
and investigating the interaction with proteins known to bind
to phosphotyrosine. Our initial test system was the prototypi-
cal SH2 phosphotyrosine binding domain from Grb2.[19] This
domain has been well characterised, binding with a high affini-
ty (Kd=200 nm) to the Shc-derived phosphotyrosine-contain-
ing hexapeptide 11 (Scheme 4).[20] We generated the required
Fmoc-/benzyl-protected amino acid 14 from Fmoc-protected
homoazidoalanine 12 and dibenzyl phosphonylacetylene 13
through a [3+2] cycloaddition in an analogous manner to our
previously reported synthesis of Fmoc-/benzyl-protected 3a
(Scheme 4).[9] Fmoc-SPPS was then used to generate peptides
11 and 15, which contain phosphotyrosine (pY) 4 and homo-
triazole (phTz) 10, respectively. We also investigated using an
Fmoc-/ethyl-protected derivative of 14 but encountered de-
protection difficulties (as reported previously[21]), so this ap-
proach was not pursued further.
For our initial assays of ligand–protein interactions, we used
full-length Grb2 that was purified as a glutathione S-transfer-
ase (GST) fusion. Titration of the pY control peptide 11 into the
protein yielded a sigmoidal binding curve (see the Supporting
Information) corresponding to an affinity of (19621) nm, con-
sistent with literature reports. The titration of phTz peptide 15
into the protein was inconclusive; although the interaction
was clearly weak it was not possible to rule out an interaction.
Protein aggregation prevented experiments at higher concen-
trations, and attempts to cleave the GST-tag enzymatically
were unsuccessful. To overcome this hurdle, the SH2 domain
was subcloned into pET28a to obtain an N-terminally His-
tagged isolated SH2 domain. The protein overexpressed well
in the insoluble fraction, which was solubilised in 8m urea and
purified by immobilised metal-affinity chromatography. On-
column refolding then yielded pure soluble protein, but size-
exclusion analysis of this protein revealed two distinct non-in-
terconverting species with identical appearance when analysed
by SDS-PAGE (Figure S4 in the Supporting Information). ITC
assay of peptide 11 binding to the two protein fractions re-
vealed that the larger (earlier-eluting) species had a significantly
reduced affinity (4.81.2) mm versus (34442) nm for the
smaller species (Figure S8). These data suggested that the early
peak represents a domain-swapped dimer (as previously ob-
served by Benfield et al.)[22] and so the later peak, correspond-
ing to monomeric His6-(Grb2-SH2) was used in all subsequent
assays, this allowed experiments to be conducted at signifi-
cantly higher (more than tenfold) protein concentrations.
The interaction of phTz peptide 15 with Grb2-SH2 was ana-
lysed by ITC. Initial experiments under our standard conditions
(final ratio of ligand to protein 2:1) were inconclusive, thus
suggesting a possible poorly defined weak binding (not
shown). The experiment was therefore repeated under low c-
value conditions[23] with a final ratio of ligand to protein of 8:1
(Figure 1B). This titration was indistinguishable from a titration
of the peptide into buffer alone, conclusively confirming no
binding. This was somewhat disappointing and surprising
given that recent work by Hofmann et al. revealed that the Src
kinase-SH2 domain can bind to phosphoarginine.[24] However,
this led us to consider that the Grb2-SH2 domain might bind
to other proteinogenic phosphoamino acids. To determine if t-
phosphohistidine 1 would bind, we synthesised a further pep-
tide, 16, that contained our phosphotriazole (pTz) analogue 2.
Again, an initial ITC experiment under standard conditions was
inconclusive (data not shown), but titration to a final ligand to
protein ratio of 8:1 (Figure 1C) yielded a clear binding interac-
tion. This was readily distinguishable from the buffer dilution
and corresponded to 1:1 binding with Kd= (71928) mm
(Figure 1). It has been shown that a 20-fold change in affinity
can be attributed to a change in protonation state.[25] The rela-
tively low affinity of the peptide 16 :Grb2-SH2 interaction ob-
Scheme 3. Proposed route to generate a protein containing the putative
phosphotyrosine analogue 10.
Scheme 4. Synthesis of Fmoc-/benzyl-protected homotriazole 14 from
Fmoc-azidohomoalanine 12 and alkyne 13, as well as peptides 11, 15 and
16, which were used in binding experiments. For full experimental proce-
dures see the Supporting information.
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served in our study might be due to a difference in protona-
tion states between the phosphate of 4 and the phosphonate
of 2. To investigate this, we conducted NMR titrations (see the
Supporting Information) that revealed the pKa of 4 to be 5.8
and 2 to be 5.95. Hence, under the conditions of our experi-
ments (pH 7.4) both phosphoryl groups should be di-anionic,
so it is unlikely that the difference in affinity is due to differing
protonation states.
To investigate the binding of other phosphoamino acids and
confirm that peptides 11 and 16 were binding at the same
site, we developed a competition
fluorescence anisotropy assay.
Titration of a phosphotyrosine-
containing peptide with an N-
terminal fluorescein, 17, with pu-
rified His6-(Grb2-SH2) (see Fig-
ure S11) yielded a binding con-
stant of (28318) nm ; this is
consistent with the Kd previously
measured by ITC. We then con-
ducted competition experiments
on all three peptides used for
ITC together with peptides 18–
21 (AcHN-Ser-Xaa-Val-Asn-Val-
Gln-NH2 Xaa=Tyr, His, pSer or
pThr, see the Supporting Infor-
mation). Binding (displacement
of 17) was observed only for
peptides 11 and 16, which con-
tain pTyr and pTz, respectively
(Figure 1D). A slightly lower than
expected IC50 of 360 mm was ob-
served for the pTz peptide; this
suggests that the ITC analysis
might have underestimated the
affinity of this peptide. No evi-
dence for binding was observed
for the other peptides (Fig-
ure S11) ; this suggested that the
Grb2-SH2 domain will not simply
bind to a phosphoryl group pre-
sented in the correct peptide
context, or to an aromatic ring.
We have shown that a proven
t-phosphohistidine mimic is ca-
pable of sequence-specific bind-
ing to a canonical phosphotyro-
sine-binding domain. Phospho-
tyrosine antibodies have previ-
ously been shown to bind to
phosphohistidine,[8b] but our
findings contradict previous
studies of phosphohistidine-con-
taining peptides binding to SH2
domains (however the condi-
tions used in these studies pre-
cluded the identification of low-
affinity binding such as we have observed and used a different
SH2 domain, from phospholipase C-g1).[26] Phosphotyrosine
binding protein modules are a common feature of human sig-
nalling proteins and, in many cases, the sequence specificity of
these domains has not been fully elucidated. The affinities of
known peptides for their target proteins also vary hugely, rang-
ing from low nanomolar to high micromolar.[27] Low affinity
therefore does not mean low significance; it is possible that
a subset of assigned phosphotyrosine binding modules could
additionally/alternatively interact with phosphohistidine-con-
Figure 1. Isothermal titration calorimetry of peptides A) 11, B) 15 and C) 16 into the Grb2 SH2 domain reveals
equilibrium binding constants of (38541) nm for 11 and (71928) mm for 16. D) A competitive fluorescence po-
larisation assay indicates an IC50 of (44280) nm for pTyr peptide 11 (&) and (36315) mm for pTz peptide 16 (&).
See the Supporting Information for control dilution experiments and full fitting of polarisation data.
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taining proteins. Further study to establish the generality of
this observation is on-going.
Experimental Section
Experimental details are given in the Supporting Information.
Acknowledgements
K.A.H. was supported by the BBSRC; T.E.M. was supported by the
EPSRC White-Rose DTC. Funding was from EPSRC (EP/I013083/1).
We would like to acknowledge work by Andrew Grimes on the
ethyl analogue of 9.
Keywords: cell signaling · phosphohistidine ·
phosphotyrosine · protein modifications · synthetic analogues
[1] P. Cohen, Nature 1982, 296, 613–620.
[2] T. Pawson, J. G. Scott, Science 1997, 278, 2075–2080.
[3] J. Schlessinger, M. A. Lemmon, Sci. STKE 2003, 2003, re12.
[4] M. B. Yaffe, A. E. Elia, Curr. Opin. Cell Biol. 2001, 13, 131–138.
[5] K. J. Treharne, R. M. Crawford, A. Mehta, Exp. Physiol. 2006, 91, 131–
139.
[6] J. M. Fujitaki, G. Fung, E. Y. Oh, R. A. Smith, Biochemistry 1981, 20, 3658–
3664.
[7] S. Srivastava, O. Zhdanova, L. Di, Z. Li, M. Albaqumi, H. Wulff, E. Y. Skol-
nik, Proc. Natl. Acad. Sci. USA 2008, 105, 14442–14446.
[8] a) G. C. McAlister, J. D. Russell, N. G. Rumachik, A. S. Hebert, J. E. P. Syka,
L. Y. Geer, M. S. Westphall, D. J. Pagliarini, J. J. Coon, Anal. Chem. 2012,
84, 2875–2882; b) S. Klumpp, J. Krieglstein, Eur. J. Biochem. 2002, 269,
1067–1071.
[9] T. E. McAllister, M. E. Webb, Org. Biomol. Chem. 2012, 10, 4043–4049.
[10] J.-M. Kee, B. Villani, L. R. Carpenter, T. W. Muir, J. Am. Chem. Soc. 2010,
132, 14327–14329.
[11] J.-M. Kee, R. C. Oslund, D. H. Perlman, T. W. Muir, Nat. Chem. Biol. 2013,
9, 416–421.
[12] P. G. Besant, P. V. Attwood, Mol. Cell. Biochem. 2009, 329, 93–106.
[13] P. V. Attwood, K. Ludwig, K. Bergander, P. G. Besant, A. Adina-Zada, J.
Krieglstein, S. Klumpp, Biochim. Biophys. Acta Proteins Proteomics 2010,
1804, 199–205.
[14] R. Serwa, I. Wilkening, G. Del Signore, M. Muhlberg, I. Claussnitzer, C.
Weise, M. Gerrits, C. P. R. Hackenberger, Angew. Chem. Int. Ed. 2009, 48,
8234–8239; Angew. Chem. 2009, 121, 8382–8387.
[15] D. B. F. Johnson, J. Xu, Z. Shen, J. K. Takimoto, M. D. Schultz, R. J.
Schmitz, Z. Xiang, J. R. Ecker, S. P. Briggs, L. Wang, Nat. Chem. Biol. 2011,
7, 779–786.
[16] H.-S. Park, M. J. Hohn, T. Umehara, L.-T. Guo, E. M. Osborne, J. Benner,
C. J. Noren, J. Rinehart, D. Sçll, Science 2011, 333, 1151–1154.
[17] A. J. Link, M. K. S. Vink, D. A. Tirrell, J. Am. Chem. Soc. 2004, 126, 10598–
10602.
[18] K. L. Kiick, E. Saxon, D. A. Tirrell, C. R. Bertozzi, Proc. Natl. Acad. Sci. USA
2002, 99, 19–24.
[19] E. Y. Skolnik, C. H. Lee, A. Batzer, L. M. Vicentini, M. Zhou, R. Daly, M. J.
Myers, J. M. Backer, A. Ullrich, M. F. White, J. Schlessinger, EMBO J. 1993,
12, 1929–1936.
[20] C. McNemar, M. E. Snow, W. T. Windsor, A. Prongay, P. Mui, R. Zhang, J.
Durkin, H. V. Le, P. C. Weber, Biochemistry 1997, 36, 10006–10014.
[21] T. E. McAllister, M. G. Nix, M. E. Webb, Chem. Commun. 2011, 47, 1297–
1299.
[22] A. P. Benfield, B. B. Whiddon, J. H. Clements, S. F. Martin, Arch. Biochem.
Biophys. 2007, 462, 47–53.
[23] W. B. Turnbull, A. H. Daranas, J. Am. Chem. Soc. 2003, 125, 14859–
14866.
[24] F. T. Hofmann, C. Lindemann, H. Salia, P. Adamitzki, J. Karanicolas, F. P.
Seebeck, Chem. Commun. 2011, 47, 10335–10337.
[25] N. J. de Mol, M. B. Gillies, M. J. E. Fischer, Bioorg. Med. Chem. 2002, 10,
1477–1482.
[26] L. Senderowicz, J.-X. Wang, L.-Y. Wang, S. Yoshizawa, W. M. Kavanaugh,
C. W. Turck, Biochemistry 1997, 36, 10538–10544.
[27] D. Kraskouskaya, E. Duodu, C. C. Arpin, P. T. Gunning, Chem. Soc. Rev.
2013, 42, 3337–3370.
Received: March 13, 2014
Published online on April 25, 2014
 2014 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim ChemBioChem 2014, 15, 1088 – 1091 1091
CHEMBIOCHEM
COMMUNICATIONS www.chembiochem.org
